Originally published at: 14 Weeks of GlucoVantage Dihydroberberine Extends GLP-1 and Weight Loss Results in Preclinical Trial
New 14-week preclinical data on GlucoVantage® dihydroberberine shows 165% GLP-1 increase at week 14 and 33.3% body weight reduction by week 13. Benefits intensified over time rather than plateauing. Natural metabolic support for the post-GLP-1 window. New long-term preclinical research on GlucoVantage® dihydroberberine from NNB Nutrition demonstrates that the natural… ..(Read more on the PricePlow Blog)